• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara’s Synchrogenix acquires ClinGenuity

Certara’s Synchrogenix acquires ClinGenuity

January 7, 2015
CenterWatch Staff

Synchrogenix, the regulatory and medical consultancy of Certara, a Princeton, N.J.-based global biosimulation technology-enabled drug development and drug safety consulting company, has acquired ClinGenuity, a Cincinnati-based artificial intelligence-assisted medical writing service. Their combined team now will include more than 200 regulatory and medical writers with experience in document development for the FDA, EMA and other global regulatory organizations.

“Large pharma and biotech companies increasingly are looking to outsource their regulatory and medical writing requirements,” said Edmundo Muniz, M.D., Ph.D., Certara CEO. “With the addition of ClinGenuity’s technology-enabled solution and experienced medical writers to our Synchrogenix team, we will be able to enhance process efficiencies and increase the offerings we can deliver to our clients.”

“With the addition of ClinGenuity’s automated redaction management capability to our existing transparency services, which include registration, disclosure documentation and clinical lay summary development, we can enable our clients to meet global transparency requirements efficiently,” said Synchrogenix CEO Kelley Kendle.

New European and U.S. clinical trial data transparency initiatives—such as EMA Policy 70, which went into effect in January 2015—are creating additional disclosure compliance requirements for pharma and biotech companies. For example, they now will need to redact and de-identify datasets in their clinical study reports and submission documents, produce research summaries suitable for a lay audience and publish their clinical study information publicly.

“We are excited to be joining Synchrogenix at this important stage in the industry’s growth; it will enable us to expand the depth and breadth of services that we can offer to our clients as they seek to meet these new regulatory requirements,” said Kleeman, who will become president of Synchrogenix.

ClinGenuity offers a range of medical writing services including development of clinical study reports, protocols and submissions, medical letters and commercial documents such as peer-reviewed articles. It also has transparency/disclosure products including redaction, lay summary and data mining services.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing